Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Reforming the Swedish pharmaceuticals market: Consequences for costs per defineddaily dose
Södertörns högskola, Huddinge, Sweden; HUI Research, Stockholm, Sweden.ORCID-id: 0000-0001-5026-9479
Umeå universitet, Samhällsvetenskapliga fakulteten, Handelshögskolan vid Umeå universitet, Nationalekonomi.ORCID-id: 0000-0003-4467-8676
Dalarna University, Sweden; HUI Resarch, Stockholm, Sweden.
2014 (Engelska)Rapport (Övrigt vetenskapligt)
Abstract [en]

In 2009, the Swedish pharmaceuticals market was reformed. One of the stated policygoals was to achieve low costs for pharmaceutical products dispensed in Sweden.

Prices and sales data for off-patent brand-name and generic pharmaceuticals have beencollected, and a log-linear regression model was used to estimate how the policy changes affected thecost per defined daily dose.

The estimated effect is a 19 percent cost reduction per defined daily dose at the retail leveland a 35 percent reduction in the prices at the wholesale level (pharmacies' purchase prices). Theempirical results suggest that half of the retail-level price reduction is due to the introduction of a pricecap for products going off patent and half is due to other components of the reform. Measured at thewholesale level the latter effect is larger than the former.

The reforms reduced the cost per defined daily dose for consumers while beingadvantageous also for the pharmacies, who saw their retail margins increase due to the reform.However, pharmaceutical firms supplying off-patent pharmaceuticals experienced a clear reduction inthe price received for their products.

Ort, förlag, år, upplaga, sidor
Stockholm: HUI Research , 2014. , s. 14
Serie
HUI Working Papers ; 105
Nyckelord [en]
Pharmaceutical industry, national pharmacy monopoly, pharmacy deregulation, competition, generics, pricing
Nationell ämneskategori
Nationalekonomi
Forskningsämne
Politik, ekonomi och samhällets organisering
Identifikatorer
URN: urn:nbn:se:umu:diva-219663OAI: oai:DiVA.org:umu-219663DiVA, id: diva2:1828778
Forskningsfinansiär
KonkurrensverketTillgänglig från: 2024-01-17 Skapad: 2024-01-17 Senast uppdaterad: 2024-01-18Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Fulltext

Person

Bergman, MatsGranlund, David

Sök vidare i DiVA

Av författaren/redaktören
Bergman, MatsGranlund, David
Av organisationen
Nationalekonomi
Nationalekonomi

Sök vidare utanför DiVA

GoogleGoogle Scholar

urn-nbn

Altmetricpoäng

urn-nbn
Totalt: 24 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf